VERONA PHARMA PLC's ticker is VRNA and the CUSIP is 925050106. A total of 89 filers reported holding VERONA PHARMA PLC in Q4 2022. The put-call ratio across all filers is 0.23 and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $1,226,000 | -63.1% | 120,000 | -82.0% | 0.17% | -63.8% |
| Q1 2022 | $3,325,000 | -38.2% | 666,339 | -16.8% | 0.47% | -20.6% |
| Q4 2021 | $5,384,000 | +22.6% | 801,256 | 0.0% | 0.59% | +60.4% |
| Q3 2021 | $4,391,000 | -16.2% | 801,256 | 0.0% | 0.37% | +4.2% |
| Q2 2021 | $5,240,000 | -21.8% | 801,256 | 0.0% | 0.35% | -31.1% |
| Q1 2021 | $6,699,000 | -7.4% | 801,256 | -22.5% | 0.51% | -19.9% |
| Q4 2020 | $7,235,000 | +15.9% | 1,033,603 | +3.4% | 0.64% | +4.7% |
| Q3 2020 | $6,240,000 | – | 1,000,000 | – | 0.61% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 1,111,112 | $11,356,000 | 29.98% |
| Aisling Capital Management LP | 1,332,485 | $13,618,000 | 9.04% |
| Abingworth LLP | 2,457,500 | $25,091,000 | 8.58% |
| Fairmount Funds Management LLC | 2,678,982 | $27,379,000 | 4.81% |
| Vivo Capital, LLC | 4,249,918 | $43,434,000 | 4.80% |
| NEA Management Company, LLC | 5,584,753 | $57,076,000 | 2.85% |
| Octagon Capital Advisors LP | 1,324,868 | $13,540,000 | 2.34% |
| Samsara BioCapital, LLC | 938,890 | $9,595,000 | 2.24% |
| ACT CAPITAL MANAGEMENT, LLC | 143,500 | $1,467,000 | 2.02% |
| Frazier Life Sciences Management, L.P. | 2,099,541 | $21,457,000 | 1.65% |